

Supplementary materials

Two New Bioactive Lignans From Leaves and Twigs of *Cleistanthus concinnus* croizat

Shi-rui Fan ^{a,b}, Jing-jing Guo ^a, Yi-ting Wang ^b, Bi-juan Yang ^a, Duo-zhi Chen ^{a*} and Xiao-jiang Hao ^{a*}

^a State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, Yunnan, PR China

^b Department of Chemical Science and Engineering, Yunnan University, Kunming 650091, Yunnan, PR China

ABSTRACT

Two new lignans (**1-2**), along with five known compounds (**3-7**) with different structures were isolated from leaves and twigs of *Cleistanthus concinnus* croizat. The new lignans were elucidated as (7'R,8'S)-3,3',5'-trimethoxy-4,4'-dihydroxy-7-en-7',9'-epoxy-8,8'-lignan (**1**) and (7'R,8'S)-3,3'-dimethoxy-4,4'-dihydroxy-7-en-7',9'-epoxy-8,8'-lignan (**2**) by comprehensive spectroscopic analysis including 1D and 2D NMR as well as HREIMS and comparing their NMR data with known compounds in the literature. Among these isolated compounds, compound **1**, **2**, **3**, and **6** were tested for anti-inflammatory effects by inhibiting NO production in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.

*Corresponding authors.

E-mail addresses: Xiao-Jiang Hao, haoxj@mail.kib.ac.cn; Duo-Zhi Chen, chenduozi@mail.kib.ac.cn,

Contents

Figure S1. ^1H NMR (500 MHz) spectrum of compound **1** in CDCl_3 .

Figure S2. ^{13}C NMR (125 MHz) spectrum of compound **1** in CDCl_3 .

Figure S3. HSQC spectrum of compound **1** in CDCl_3 .

Figure S4. ^1H - ^1H COSY spectrum of compound **1** in CDCl_3 .

Figure S5. HMBC spectrum of compound **1** in CDCl_3 .

Figure S6. ROESY spectrum of compound **1** in CDCl_3 .

Figure S7. HRESI(+)MS spectrum of compound **1**.

Figure S8. UV spectrum of compound **1**.

Figure S9. IR spectrum of compound **1**.

Figure S10. ^1H NMR (500 MHz) spectrum of compound **2** in CDCl_3 .

Figure S11. ^{13}C NMR (125 MHz) spectrum of compound **2** in CDCl_3 .

Figure S12. HSQC spectrum of compound **2** in CDCl_3 .

Figure S13. ^1H - ^1H COSY spectrum of compound **2** in CDCl_3 .

Figure S14. HMBC spectrum of compound **2** in CDCl_3 .

Figure S15. ROESY spectrum of compound **2** in CDCl_3 .

Figure S16. HRESI(+)MS spectrum of compound **2**.

Figure S17. UV spectrum of compound **2**.

Figure S18. IR spectrum of compound **2**.

Figure S19. Key ^1H - ^1H COSY, HMBC and ROESY correlations of compound **1** and compound **2**.

Table S1. ^1H (500 MHz) and ^{13}C (125 MHz) NMR data of compound **1-2** in CDCl_3 .

Table S2. Inhibitory effects on NO production in LPS-stimulated RAW264.7 cells.

Table S3. IC_{50} of Inhibitory effects on NO production of **1**, **2**, and **6**




Figure S1. ^1H NMR (500 MHz) spectrum of compound **1** in CDCl_3 .




Figure S2. ^{13}C NMR and DEPT (125 MHz) spectrum of compound **1** in CDCl_3 .




Figure S3. HSQC spectrum of compound **1** in CDCl₃.




Figure S4. ¹H-¹H COSY spectrum of compound **1** in CDCl₃.




Figure S5. HMBC spectrum of compound **1** in CDCl₃.




Figure S6. ROESY spectrum of compound **1** in CDCl₃.




Figure S7. HRESI(+)MS spectrum of compound **1**.




Figure S8. UV spectrum of compound **1**.




Figure S9. IR spectrum of compound **1**.




Figure S10. ¹H NMR (500 MHz) spectrum of compound **2** in CDCl₃.

hbb10
hbb10 c13 and dept




Figure S11. ^{13}C NMR and DEPT (125 MHz) spectrum of compound **2** in CDCl_3 .




Figure S12. HSQC spectrum of compound **2** in CDCl_3 .




Figure S13. ^1H - ^1H COSY spectrum of compound **2** in CDCl_3 .




Figure S14. HMBC spectrum of compound **2** in CDCl_3 .




Figure S15. ROESY spectrum of compound **2** in CDCl₃.




Figure S16. HRESI(+)-MS spectrum of compound **2**.




Figure S17. UV spectrum of compound2.




Figure S18. IR spectrum of compound **2**.




Figure S19. Key ^1H - ^1H COSY, HMBC and ROESY correlations of compound **1** and compound **2**.

Table S1. ¹H (500 MHz) and ¹³C (125 MHz) NMR data of compound **1-2** in CDCl₃.

1			2	
No.	δ_{H}	δ_{C}	δ_{H}	δ_{C}
1		129.9		129.9
2	6.7 (d, 1.8)	110.7	6.69 (d, 1.8)	110.7
3		144.5		144.5
4		146.5		146.4
5	6.92 (d, 8.8)	114.6	6.90 (d, 8.4)	114.0
6	6.7 ^a	121.3	6.7 ^a	121.3
7	6.19 (m)	119.8	6.19 (m)	119.7
8		143.8		144.0
9	5.00 (m), 4.7 (m)	70.2	4.99 (m), 4.7 (m)	70.2
1'		131.5		132.3
2'	6.65 (s)	103.3	6.96 (d, 1.5)	108.7
3'		147.0		146.7
4'		134.5		145.5
5'		147.0	6.90 (d, 8.4)	114.5
6'	6.65 (s)	103.3	6.87 (dd, 8.4, 1.5)	120.0
7'	4.19 (d, 9.6)	87.6	4.21 (d, 9.6)	87.3
8'	2.68 (m)	47.7	2.67 (m)	47.6
9'	1.18 (d, 6.6)	14.2	1.17 (d, 6.6)	14.2
4-OH	5.64 (brs)		5.62 (brs)	
4'-OH	5.53 (brs)		5.62 (brs)	
3-OCH ₃	3.91 (s)	55.9	3.91 (s)	55.9
3'-OCH ₃	3.90 (s)	56.3	3.91 (s)	55.9
5'-OCH ₃	3.90 (s)	56.3		

^[a]Overlapped signals are reported without designating multiplicity.

Table S2. Inhibitory effects on NO production in LPS-stimulated RAW 264.7 cells.

Compound	Concentration (μM)	NO inhibition rate(%)
L-NMMA ^a	50	54.02±0.91
1	25	39.85±1.34
2	25	25.18±4.46
3	25	-0.47±0.82
6	25	28.65±1.93

^aL-NMMA (NG-monomethyl-L-arginine): positive control.

Table S3. IC₅₀ of Inhibitory effects on NO production of **1**, **2**, and **6**

Compounds	IC ₅₀ (μM)	
	Mean	SD
1	45.1	8.1
2	53.6	9.0
6	62.3	7.8
L-NMMA	38.6	7.6